Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-007042
Filing Date
2023-04-27
Accepted
2023-04-27 16:01:35
Documents
73
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q icpt-20230331x10q.htm   iXBRL 10-Q 1670796
2 EX-31.1 icpt-20230331xex31d1.htm EX-31.1 9879
3 EX-31.2 icpt-20230331xex31d2.htm EX-31.2 9862
4 EX-32.1 icpt-20230331xex32d1.htm EX-32.1 10343
  Complete submission text file 0001558370-23-007042.txt   8363335

Data Files

Seq Description Document Type Size
5 EX-101.SCH icpt-20230331.xsd EX-101.SCH 50938
6 EX-101.CAL icpt-20230331_cal.xml EX-101.CAL 72176
7 EX-101.DEF icpt-20230331_def.xml EX-101.DEF 223038
8 EX-101.LAB icpt-20230331_lab.xml EX-101.LAB 474544
9 EX-101.PRE icpt-20230331_pre.xml EX-101.PRE 383868
67 EXTRACTED XBRL INSTANCE DOCUMENT icpt-20230331x10q_htm.xml XML 1802203
Mailing Address 305 MADISON AVENUE MORRISTOWN NJ 07960
Business Address 305 MADISON AVENUE MORRISTOWN NJ 07960 646-747-1000
INTERCEPT PHARMACEUTICALS, INC. (Filer) CIK: 0001270073 (see all company filings)

EIN.: 223868459 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35668 | Film No.: 23856615
SIC: 2834 Pharmaceutical Preparations